ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

zoetis israel holding b.v., israel - atipamezole hydrochloride - תמיסה להזרקה - atipamezole hydrochloride 5 mg/ml

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - dexmedetomidine hydrochloride 0.5 mg/ml - solution for injection - non-invasive mildly to moderately painful procedures and examinations which require restraint sedation and analgesia in dogs and cats. premedication in cats before induction and maintenance of general anaesthesia with ketamine. deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures. premedication in dogs before induction and maintenance of general anaesthesia.

ישראל - עברית - Ministry of Health

cts ltd - levetiracetam - תמיסה - levetiracetam 100 mg/ml - levetiracetam - levetiracetam - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. keppra is indicated as adjunctive therapy - in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

ישראל - עברית - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 250 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

ישראל - עברית - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 500 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

ישראל - עברית - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 1000 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 250 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 500 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.